FindTrial
Sign In

Effect of warfarin and rivaroxaban in coronary endartherectomy

Assesment and compair the prognosis of warfarin and rivaroxaban in patient with open heart surgery and endarterectomy

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20181124041746N1
Enrollment
120
Registered
2019-01-19
Start date
2018-11-22
Completion date
Unknown
Last updated
2019-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Coronary arthry disease. Condition 2: . Atherosclerotic heart disease

Interventions

Intervention 1: In one group, patients recieve warfarin (vitamink antagonist)for 3 monthThe dosage of drug was baced on patients INR. Goal INR was 2-3.we check INR frequently to acheive this goal.

Sponsors

Kermanshah University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients undergoing CABG and endarterectomy

Exclusion criteria

Exclusion criteria: Patients with prosthetic valve ESRD patents

Design outcomes

Primary

MeasureTime frame
Bleeding. Timepoint: 3rd day then 3rd month. Method of measurement: Questinannair-interview.;Cerebrovascular accident. Timepoint: 3rd day and 3rd month. Method of measurement: Quastionnair-interview.;Cardiovascular complcation. Timepoint: 3rd day and 3rd month. Method of measurement: Questionnair-interview.;Thromboembolism. Timepoint: 3rd day and3rd month. Method of measurement: Questionnair-interview.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDelnia Rahimpour

Kermanshah University of Medical Sciences

Dilniya.rahimpour@gmail.com+98 83 3836 0041

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026